Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9860104 | PMC |
| http://dx.doi.org/10.1016/j.stemcr.2022.11.022 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Androgen therapy in midlife and older women: a position statement of the Latin American Association of Gynecological Endocrinology (ALEG).
Climacteric
September 2025
Escuela de Postgrado en Salud, Universidad Espíritu Santo, Samborondón, Ecuador.
Objective: Androgens have been prescribed to alleviate symptoms in midlife women, but evidence regarding benefits and risks remains limited, with no clearly established indications for Testosterone therapy. In many Latin American countries, Testosterone is prescribed without specific guidelines, making it difficult to identify patients who might benefit. This position statement aims to summarize evidence and provide a Latin American perspective on androgen therapy in midlife and older women.
View Article and Find Full Text PDFCrosstalk between mitochondrial dysfunction and benign prostatic hyperplasia: unraveling the intrinsic mechanisms.
Can J Urol
August 2025
Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China.
Benign prostatic hyperplasia (BPH) represents a prevalent etiology of lower urinary tract symptoms (LUTS) in the male population, clinically defined by a non-malignant proliferation of prostatic tissue. While BPH exhibits a high prevalence among older male populations globally, the precise underlying mechanisms contributing to its development remain incompletely elucidated. Mitochondria, essential organelles within eukaryotic cells, are critical for cellular bioenergetics, the regulation of reactive oxygen species (ROS) generation, and the modulation of cell death pathways.
View Article and Find Full Text PDFIntroduction: Androgen receptor signaling inhibitors (ARSIs) improve survival in prostate cancer; however, it may increase cardiovascular risks, especially in elderly patients with heart disease.
Case Presentation: A 94-year-old man with aortic valve stenosis, hypertension, and diabetes had a nodal metastatic progression of prostate cancer at 88 years of age, leading to the implementation of androgen deprivation therapy (ADT). After 5 years of therapy, prostate-specific antigen (PSA) re-elevated; however, ADT was maintained.
ECD, a novel androgen receptor target promotes prostate cancer tumorigenesis by regulating glycolysis.
Oncogene
September 2025
Department of Genetics, Cell Biology and Anatomy, University of Nebraska Medical Center, 985805 Nebraska Medical Center, Omaha, NE, USA.
Androgen receptor (AR)-mediated signaling is essential for PC tumorigenesis. In the TCGA database we observed a positive correlation between ECD and AR expression. Consistently, Dihydrotestosterone (DHT) treatment of PC cell lines increased ECD mRNA and protein levels, and AR knockdown (KD) reduced ECD expression.
View Article and Find Full Text PDFTreatment Landscape for Older Men With Metastatic Hormone-Sensitive Prostate Cancer in the United States.
Cancer Med
September 2025
University of North Texas Health Science Center, Fort Worth, Texas, USA.
Objective: This study evaluated treatment patterns and factors associated with androgen deprivation therapy (ADT) intensification with androgen receptor pathway inhibitors (ARPI) and/or docetaxel among older men with mHSPC in the United States.
Methods: The study utilized a retrospective cohort of 6850 older men (age ≥ 67 years) diagnosed with mHSPC between July 2016 and December 2019 from the Surveillance, Epidemiology, and End Results Medicare-linked database. Men must maintain continuous enrollment in Medicare fee-for-service Parts A/B/D for ≥ 12 months before mHSPC diagnosis and ≥ 6 months after diagnosis.